Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 15 Issue 2, February 2016

Comment

Top of page ⤴

News and Analysis

  • FDA approval rate continues to surge, with 45 green lights for new drugs granted in 2015.

    • Asher Mullard
    News and Analysis
Top of page ⤴

News in Brief

Top of page ⤴

Biobusiness Briefs

Top of page ⤴

An Audience With

  • Michael Hanson, president of the GPCR Consortium, discusses how industry and academic partners are shedding light on one of the most important classes of drug targets.

    An Audience With
Top of page ⤴

From the Analyst's Couch

  • This analysis presents anticancer drug combinations that contain two or more targeted agents and discusses their impact on oncology markets.

    • Rachel M. Webster
    From the Analyst's Couch
Top of page ⤴

Research Highlight

Top of page ⤴

In Brief

Top of page ⤴

Opinion

  • Over the past decade, the drug–target residence time model has been broadly applied to drug discovery programmes across multiple therapeutic areas. To mark the 10 year anniversary of this model, Copeland discusses the benefits of assessing residence time, highlighting some of the advances in its theory and application.

    • Robert A. Copeland
    Opinion
Top of page ⤴

Review Article

  • Optogenetics has already had a major impact on neuroscience research, particularly in the study of cognitive and emotional processes. Here, Song and Knöpfel discuss emerging applications of optogenetic technologies, focusing on their potential to transform neuroscience drug discovery programmes and to provide novel therapeutic approaches for conditions such as Parkinson disease, mood disorders and epilepsy.

    • Chenchen Song
    • Thomas Knöpfel
    Review Article
  • CNS myeloid cells mediate the local immune response during development, health and brain diseases and are emerging as potential therapeutic targets for the treatment of neurological and psychiatric disorders. Here, Biber and colleagues assess strategies for targeting CNS myeloid cells and consider key issues associated with their clinical translation.

    • Knut Biber
    • Thomas Möller
    • Marco Prinz
    Review Article
  • Cells within the microvascular compartment, particularly leukocytes, can affect angiogenesis, inflammation and fibrosis. Kreuger and Phillipson discuss how to target these cells therapeutically, focusing on ways to interfere with intracellular communication and reprogramme leukocytes, which could have applications in the design of drugs and their delivery systems.

    • Johan Kreuger
    • Mia Phillipson
    Review Article
Top of page ⤴

Corrigendum

Top of page ⤴

Correspondence

Top of page ⤴

Erratum

Top of page ⤴

Search

Quick links